Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids.
HRA Pharma, under license from the Research Triangle Institute, is developing ulipristal, a progesterone receptor modulator, for the potential use as a contraceptive and an emergency contraceptive, and for the potential treatment of uterine fibroids. Phase II clinical trials for uterine fibroids and phase III trials for contraception are underway. The drug was expected to be launched in the US and Europe in 2009.
Orihuela
Pedro A
PA
Universidad de Santiago de Chile, Laboratorio de Inmunología de la Reproducción, Facultad de Química y Biología, Santiago 9170022, Chile. porihuela@usach.cl
D000818:Animals; D003271:Contraceptive Agents, Female; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D009649:Norpregnadienes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
D003271:Contraceptive Agents, Female; D009649:Norpregnadienes; D011980:Receptors, Progesterone; C094854:ulipristal